Skip to main content
. Author manuscript; available in PMC: 2022 May 27.
Published in final edited form as: Lung. 2020 Jan 1;198(1):95–103. doi: 10.1007/s00408-019-00310-8

Table 4.

Ranking of treatments

P-score
Dupilumab 0.83
Mepolizumab 0.66
Reslizumab 0.62
Benralizumab 0.36
Placebo 0.00

P-scores are based solely on the point estimates and standard errors of the network estimates